Everpoint Asset Management adds EXACT Sciences Corporation (EXAS) to its portfolio

EXACT Sciences Corporation (EXAS) : Everpoint Asset Management added new position in EXACT Sciences Corporation during the most recent quarter end. The investment management firm now holds 2,000,000 shares of EXACT Sciences Corporation which is valued at $42,380,000 , the company said in a statement filed on Aug 15, 2016 with the SEC.EXACT Sciences Corporation makes up approximately 1.11% of Everpoint Asset Management’s portfolio.

Other Hedge Funds, Including , Casdin Capital sold out all of its stake in EXAS during the most recent quarter. The investment firm sold 60,000 shares of EXAS which is valued $1,271,400. Verity Asset Management sold out all of its stake in EXAS during the most recent quarter. The investment firm sold 19,741 shares of EXAS which is valued $418,312.Victory Capital Management Inc boosted its stake in EXAS in the latest quarter, The investment management firm added 11 additional shares and now holds a total of 545 shares of EXACT Sciences Corporation which is valued at $11,358.

EXACT Sciences Corporation closed down -0.275 points or -1.49% at $18.195 with 25,86,572 shares getting traded on Thursday. Post opening the session at $18.85, the shares hit an intraday low of $17.87 and an intraday high of $18.85 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.

On the company’s financial health, EXACT Sciences Corporation reported $-0.46 EPS for the quarter, beating the analyst consensus estimate by $ 0.09 according to the earnings call on Jul 26, 2016. Analyst had a consensus of $-0.55. The company had revenue of $21.20 million for the quarter, compared to analysts expectations of $18.50 million. The company’s revenue was up 161.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.44 EPS.

Many Wall Street Analysts have commented on EXACT Sciences Corporation. Company shares were Reiterated by Craig Hallum on Jul 27, 2016 to “Buy”, Firm has raised the Price Target to $ 26 from a previous price target of $18 .Company shares were Reiterated by Jefferies on Jul 27, 2016 to “Buy”, Firm has raised the Price Target to $ 20 from a previous price target of $13 .Company shares were Reiterated by The Benchmark Company on Jul 27, 2016 to “Hold”, Firm has raised the Price Target to $ 14 from a previous price target of $9 .

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The Company has developed a non?invasive screening test called Cologuard for colorectal cancer. Its Cologuard test is a non?invasive stool?based deoxyribonucleic acid (DNA) (sDNA) screening test designed to detect DNA markers. In addition to DNA markers its test includes a protein marker to detect blood in the stool utilizing an antibody?based fecal immunochemical test (FIT). The Company’s Cologuard test is designed to detect pre?cancerous lesions or polyps and each of the four stages of colorectal cancer. By detecting pre?cancers and cancers early with its test affected patients can be referred to colonoscopy during which the polyps or lesions can be removed. The company’s test also detects blood in stool utilizing an antibody based FIT test.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

EXACT Sciences Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on EXACT Sciences Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.